Skip to main content

ALK Positive clinical trials at UC Health
2 in progress, 1 open to new patients

  • Targeted Chemotherapy, Crizotinib, or Placebo in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer after surgery

    β€œCan targeted chemotherapy, Crizotinib, stop the growth of tumor cells by blocking the a protein from working?”

    open to eligible people ages 18 years and up

    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

    at UCSD UC Davis

  • Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    Sorry, in progress, not accepting new patients

    This phase I/II trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase I completed 2/15/13)

    at UCSF

Last updated: